ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, Y.
Right arrow Articles by Ding, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, Y.
Right arrow Articles by Ding, Y.
Annals of Clinical & Laboratory Science 37:15-21 (2007)
© 2007 Association of Clinical Scientists

Diagnosis and Treatment of Gastrointestinal Stromal Tumors of the Stomach: Report of 28 Cases.

Yafu Wu, Xinhua Zhu and Yitao Ding
Department of General Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China

Address correspondence to Yafu Wu, M.D., Department of General Surgery, Affiliated Drum Tower Hospital, Zhongshang Road 321, Nanjing 210008, China; tel 86 25 8330 4616; fax 86 25 8331 7016; e-mail drzhuxh{at}hotmail.com.

We retrospectively analyzed 28 patients with gastric gastrointestinal stromal tumors (GISTs) at our hospital to investigate their clinical features, diagnosis, and treatment. All patients underwent surgical resection. There were 18 cases with subtotal gastrectomy, 8 cases with partial gastrectomy, 1 case with total gastrectomy, and 1 case with subtotal gastrectomy combined with right hemihepatectomy. Based on pathological findings, the tumors were benign in 16 cases (57%), borderline in 2 cases (7%), and malignant in 10 cases (36%). The tumor diameter was significantly correlated with the malignancy of gastric GISTs (3.5 ± 1.6 cm in benign tumors, vs 7.5 ± 1.3 cm in malignant tumors, p <0.05). Immunohistochemical staining for CD117 and CD34 was positive in 26 (93%) and 17 (61%), respectively. The mean follow-up period ranged from 6 to 60 mo in 23 of the patients, and the other 5 patients (all with benign tumors) were lost to follow-up. No recurrence or metastasis was found in patients with benign gastric GISTs. Four cases of malignant GISTs (17%, 4/23) had liver metastasis or intra-abdominal dissemination, and 2 of them received a second resection for liver metastasis. Four cases of malignant gastric GISTs died with tumors more than 10 cm in maximum diameter, 3 of them died of liver metastasis and multiple organ failure, and 1 died of myocardial infarction. Excluding 2 patients with benign tumors that were followed for <3 yr, the 3-yr survival rate was 81% (17/21) in this group, and 60% (6/10) in the patients with malignant gastric GISTs. In conclusion, the prognosis is related to the tumor size and the number of mitoses seen on histological examination. Positive detection of CD117, combined with other markers and pathological features, is of great importance in the differential diagnosis of gastric GISTs. Complete resection with negative margins remains the fundamental objective in the surgical management of gastric GISTs.

Keywords: gastrointestinal stromal tumors, CD117 marker, c-KIT proto-oncogene, gastric malignancies






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Association of Clinical Scientists.